Blair William & Co. IL Has $1.39 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Blair William & Co. IL cut its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 14.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,882 shares of the company’s stock after selling 6,769 shares during the period. Blair William & Co. IL’s holdings in Ionis Pharmaceuticals were worth $1,394,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in IONS. Itau Unibanco Holding S.A. raised its stake in shares of Ionis Pharmaceuticals by 40.9% in the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock valued at $43,000 after acquiring an additional 314 shares during the last quarter. Xponance Inc. raised its position in Ionis Pharmaceuticals by 1.7% in the 4th quarter. Xponance Inc. now owns 19,339 shares of the company’s stock valued at $676,000 after purchasing an additional 318 shares during the last quarter. Amalgamated Bank boosted its stake in Ionis Pharmaceuticals by 3.4% in the fourth quarter. Amalgamated Bank now owns 10,292 shares of the company’s stock worth $360,000 after purchasing an additional 335 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in Ionis Pharmaceuticals by 6.6% in the fourth quarter. Vontobel Holding Ltd. now owns 5,865 shares of the company’s stock worth $205,000 after purchasing an additional 363 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Ionis Pharmaceuticals by 1.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 21,826 shares of the company’s stock worth $763,000 after purchasing an additional 373 shares during the last quarter. 93.86% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on IONS shares. StockNews.com upgraded shares of Ionis Pharmaceuticals to a “sell” rating in a research report on Tuesday, March 18th. BMO Capital Markets reduced their target price on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating on the stock in a research report on Thursday, February 20th. Redburn Atlantic started coverage on shares of Ionis Pharmaceuticals in a research note on Monday. They set a “neutral” rating and a $39.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $70.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $58.37.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Patrick R. O’neil sold 1,207 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $32.35, for a total transaction of $39,046.45. Following the completion of the transaction, the executive vice president now owns 56,245 shares in the company, valued at approximately $1,819,525.75. This represents a 2.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Brett P. Monia sold 38,843 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $31.65, for a total value of $1,229,380.95. Following the completion of the sale, the chief executive officer now owns 180,683 shares in the company, valued at approximately $5,718,616.95. This trade represents a 17.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,956 shares of company stock worth $3,608,439 over the last ninety days. Company insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Stock Performance

IONS stock opened at $28.71 on Thursday. Ionis Pharmaceuticals, Inc. has a 1-year low of $27.00 and a 1-year high of $52.34. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12. The firm has a market cap of $4.56 billion, a PE ratio of -9.44 and a beta of 0.28. The business’s 50-day moving average price is $32.32 and its two-hundred day moving average price is $35.47.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The business had revenue of $227.00 million for the quarter, compared to analysts’ expectations of $140.97 million. During the same quarter in the previous year, the business posted $0.12 EPS. Ionis Pharmaceuticals’s revenue for the quarter was down 30.2% on a year-over-year basis. As a group, research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.